|1.||Song, Dan-Qing: 2 articles (07/2004 - 05/2003)|
|2.||Jiang, Jian-Dong: 2 articles (07/2004 - 05/2003)|
|3.||Li, Jian-Nong: 2 articles (07/2004 - 05/2003)|
|4.||Bekesi, George: 1 article (05/2003)|
|5.||Hu, Qiong-Ying: 1 article (05/2003)|
|6.||Yin, Lu: 1 article (05/2003)|
|7.||Holland, James F: 1 article (05/2003)|
|8.||Lin, Yi-He: 1 article (05/2003)|
07/01/2004 - "[Antitumor mechanism of 3-bromopropionylamino benzoylurea on leukemia and lymphoma]."
07/01/2004 - "JIMB01 increased the activities of caspase-3, -8 and -9 in CEM cells; DEVD-fmk, a caspase-3 inhibitor, inhibited the cytotoxicity of JIMB01 in CEM leukemia cells. "
07/01/2004 - "DNA degradation in the form of a multiple-unit DNA ladder was clearly demonstrated in CEM leukemia cells treated with JIMB01 at 0.15 micromol x L(-1) or higher for 24 h using agarose gel electrophoresis. "
07/01/2004 - "To study the antitumor mechanism of 3-bromopropionylamino benzoylurea (JIMB01) on leukemia and lymphoma. "
07/01/2004 - "The antitumor mechanism of JIMB01 is that JIMB01 may induce tumor cell apoptosis through Bcl-2 phosphorylation and then caspase passway."
05/15/2003 - "Since JIMB01 is a small compound, targets a specific molecule in tumor cells, and has promising activity against human hepatocarcinoma in vivo, we believe JIMB01 merits consideration for further investigation."
05/15/2003 - "Furthermore, in vivo experiments using nude mice showed that intraperitoneal injection of JIMB01 at 15mg/kg (with seven injections at 4-day intervals) significantly inhibited the growth of a human hepatocarcinoma (BEL-7402) by 66% in tumor volume (P=0.01), at least compatible to the inhibition by vincristine (43% inhibition), indicating good bioavailability of the compound in the circulation. "
|2.||Caspase 3 (Caspase-3)
|5.||DNA (Deoxyribonucleic Acid)